Skip to content

Released Mar 10, 2022, after the close

10-K filed Mar 11, 2022, 70 days after period end · 0001564590-22-009855

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$60.26MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$62,889,000N/M
Operating Cash Flowderived-$19,362,000N/M
Free Cash Flowderived-$19,380,000N/M

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020Q4 2019Q4 2018
Revenue—$1.04M$4.77M$3.74M
Net Income-$60.26M-$39.42M-$27.08M-$26.16M
EPS Diluted—-$1.11-$0.99-$1.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR